Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACERNYSE:ATNMNASDAQ:PYRGFNYSE:VHAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACERAcer Therapeutics$0.66$0.74$0.55▼$4.56$16.15MN/AN/A574,675 shsATNMActinium Pharmaceuticals$1.65-2.9%$1.54$1.03▼$8.64$51.47M-0.27506,214 shs164,342 shsPYRGFPyroGenesis Canada$0.33+1.8%$0.34$0.30▼$0.80$61.94M0.8911,053 shs20,787 shsVHAQViveon Health Acquisition$11.00$11.00$0.00▼$12.48$62.26M-0.112 shs99 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACERAcer Therapeutics0.00%0.00%0.00%0.00%0.00%ATNMActinium Pharmaceuticals+11.84%+18.88%+3.66%-9.09%-79.14%PYRGFPyroGenesis Canada-5.45%-5.83%-0.24%-15.21%-34.80%VHAQViveon Health Acquisition0.00%0.00%0.00%0.00%+10.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACERAcer TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AATNMActinium Pharmaceuticals1.2506 of 5 stars3.42.00.00.00.00.00.6PYRGFPyroGenesis Canada0.1451 of 5 stars0.02.00.00.00.61.70.0VHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACERAcer Therapeutics 0.00N/AN/AN/AATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00142.42% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/AVHAQViveon Health Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ACER, VHAQ, PYRGF, and ATNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/1/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/25/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACERAcer TherapeuticsN/AN/AN/AN/AN/AN/AATNMActinium Pharmaceuticals$81K635.47N/AN/A$1.31 per share1.26PYRGFPyroGenesis Canada$9.14M6.78N/AN/A($0.01) per share-33.18VHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACERAcer Therapeutics-$26.24MN/A0.00∞N/AN/AN/AN/AN/AATNMActinium Pharmaceuticals-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/APYRGFPyroGenesis Canada-$21.12M-$0.02N/A∞N/A-115.14%N/A-60.81%N/AVHAQViveon Health Acquisition-$610KN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACERAcer TherapeuticsN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACERAcer TherapeuticsN/AN/AN/AATNMActinium PharmaceuticalsN/A10.2510.25PYRGFPyroGenesis CanadaN/A0.600.50VHAQViveon Health AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACERAcer TherapeuticsN/AATNMActinium Pharmaceuticals27.50%PYRGFPyroGenesis Canada0.03%VHAQViveon Health Acquisition22.14%Insider OwnershipCompanyInsider OwnershipACERAcer Therapeutics20.20%ATNMActinium Pharmaceuticals6.00%PYRGFPyroGenesis Canada47.68%VHAQViveon Health Acquisition75.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACERAcer Therapeutics3024.46 million19.52 millionNot OptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionablePYRGFPyroGenesis Canada90186.69 million96.34 millionNo DataVHAQViveon Health Acquisition25.66 million1.40 millionNot OptionableACER, VHAQ, PYRGF, and ATNM HeadlinesRecent News About These CompaniesViveon Health Acquisition CorpNovember 21, 2024 | investing.comClearday, Inc. (CLRD)September 6, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - UpdatedMay 3, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future SuccessMay 2, 2024 | finance.yahoo.comViveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination ProcessFebruary 28, 2024 | finanznachrichten.deVIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESSFebruary 27, 2024 | globenewswire.comNYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)February 21, 2024 | finance.yahoo.comViveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSEDecember 27, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)December 22, 2023 | tmcnet.comSan Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.November 13, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)October 24, 2023 | finance.yahoo.comVHAQ-R Viveon Health Acquisition Corp.September 23, 2023 | seekingalpha.comViveon Health Acquisition Received Audit Opinion With Going Concern ExplanationSeptember 15, 2023 | marketwatch.comVIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATIONSeptember 15, 2023 | finance.yahoo.comViveon Healthcare Increases Consideration Offered to Clearday ShareholdersSeptember 5, 2023 | finance.yahoo.comSPAC Viveon ups merger consideration for Clearday to $500MAugust 29, 2023 | msn.comViveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger AgreementAugust 29, 2023 | finance.yahoo.comVIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILINGApril 25, 2023 | finance.yahoo.comViveon Health Acquisition Corp. (VHAQ-RT)April 18, 2023 | finance.yahoo.com(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to MarketApril 12, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACER, VHAQ, PYRGF, and ATNM Company DescriptionsAcer Therapeutics NASDAQ:ACERAcer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.Actinium Pharmaceuticals NYSE:ATNM$1.65 -0.05 (-2.94%) Closing price 04:00 PM EasternExtended Trading$1.64 0.00 (-0.30%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.PyroGenesis Canada NASDAQ:PYRGF$0.33 +0.01 (+1.78%) As of 03:45 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Viveon Health Acquisition NYSE:VHAQ$11.00 0.00 (0.00%) As of 01/30/2025Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
